Lexicon Pharmaceuticals Inc (LXRX) — Cash Flow-to-Debt Ratio
Lexicon Pharmaceuticals Inc (LXRX) has a Cash Flow-to-Debt Ratio of -0.22x as of March 2026, meaning its operating cash flow of $-14.73 Million could theoretically repay 0% of its total liabilities ($65.96 Million) in one year. See LXRX free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Lexicon Pharmaceuticals Inc Cash Flow-to-Debt Ratio (1999–2025)
Historical debt coverage capacity for Lexicon Pharmaceuticals Inc across 27 annual periods. Also explore LXRX net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Lexicon Pharmaceuticals Inc (1999–2025)
Year-by-year debt coverage analysis for Lexicon Pharmaceuticals Inc. For market capitalisation and broader financial context, see Lexicon Pharmaceuticals Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.88x | $-67.85 Million | $77.45 Million | ▲ +25.3% |
| 2024 | -1.17x | $-178.78 Million | $152.47 Million | ▲ +1.3% |
| 2023 | -1.19x | $-161.90 Million | $136.32 Million | ▼ -3.2% |
| 2022 | -1.15x | $-88.85 Million | $77.17 Million | ▲ +69.2% |
| 2021 | -3.73x | $-87.02 Million | $23.31 Million | ▼ -23.8% |
| 2020 | -3.02x | $-142.97 Million | $47.42 Million | ▼ -896.4% |
| 2019 | 0.38x | $113.81 Million | $300.61 Million | ▲ +179.1% |
| 2018 | -0.48x | $-148.61 Million | $310.54 Million | ▲ +0.8% |
| 2017 | -0.48x | $-185.39 Million | $384.44 Million | ▲ +12.6% |
| 2016 | -0.55x | $-175.63 Million | $318.22 Million | ▼ -210.2% |
| 2015 | 0.50x | $184.78 Million | $368.98 Million | ▲ +224.1% |
| 2014 | -0.40x | $-75.62 Million | $187.36 Million | ▲ +53.9% |
| 2013 | -0.88x | $-91.08 Million | $104.00 Million | ▲ +2.6% |
| 2012 | -0.90x | $-94.46 Million | $105.10 Million | ▼ -35.9% |
| 2011 | -0.66x | $-87.94 Million | $132.94 Million | ▲ +3.7% |
| 2010 | -0.69x | $-82.37 Million | $119.86 Million | ▲ +27.2% |
| 2009 | -0.94x | $-89.02 Million | $94.26 Million | ▲ +35.1% |
| 2008 | -1.46x | $-95.60 Million | $65.68 Million | ▼ -62.0% |
| 2007 | -0.90x | $-74.32 Million | $82.72 Million | ▼ -65.4% |
| 2006 | -0.54x | $-56.91 Million | $104.77 Million | ▼ -408.0% |
| 2005 | 0.18x | $23.44 Million | $132.91 Million | ▲ +137.7% |
| 2004 | -0.47x | $-42.26 Million | $90.39 Million | ▼ -614.8% |
| 2003 | -0.07x | $-7.72 Million | $117.98 Million | ▲ +92.8% |
| 2002 | -0.90x | $-28.79 Million | $31.87 Million | ▼ -8.6% |
| 2001 | -0.83x | $-17.99 Million | $21.62 Million | ▼ -624.1% |
| 2000 | -0.11x | $-1.50 Million | $13.06 Million | ▲ +83.1% |
| 1999 | -0.68x | $-9.60 Million | $14.10 Million | — |